COMMUNIQUÉS West-GlobeNewswire

Fortrea et Emery Pharma annoncent une collaboration stratégique visant à mener des études sur les interactions médicamenteuses répondant aux normes de la FDA en utilisant la rifampicine
24/06/2025
Cette collaboration permet la réalisation de tests de détection des impuretés de nitrosamine offrant aux promoteurs la possibilité de démontrer l’utilisation acceptable de la rifampicine dans les études sur les [...]
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
24/06/2025
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of [...]
Le Dr Mark Kirchhof nommé président de l’Association canadienne de dermatologie
24/06/2025
OTTAWA, 24 juin 2025 (GLOBE NEWSWIRE) -- L’Association canadienne de dermatologie (ACD) est fière d’annoncer la nomination du Dr Mark Kirchhof au poste de président de l’ACD. Il assumera ses fonctions à compter du 19 [...]
Dr. Mark Kirchhof appointed President of the Canadian Dermatology Association
24/06/2025
OTTAWA, June 24, 2025 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Mark Kirchhof as CDA President, effective June 19, 2025. Dr. Mark Kirchhof is a [...]
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
24/06/2025
Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS [...]
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
24/06/2025
-- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with [...]
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
24/06/2025
MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the [...]
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
24/06/2025
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization [...]
Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use
24/06/2025
SAVONA, Italy, June 24, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance [...]
Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction
24/06/2025
Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo [...]
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
24/06/2025
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing [...]
Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
24/06/2025
Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the [...]
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
24/06/2025
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short [...]
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
24/06/2025
Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE [...]
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
24/06/2025
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA ® IN EUROPE Vazkepa ® supported by strong clinical data package and expected to contribute to Specialty & Primary [...]
DARZALEX® (daratumumab) reçoit le premier avis favorable du CHMP pour les patients atteints d’un myélome multiple indolent à haut risque
24/06/2025
En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, [...]
Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique
24/06/2025
L’analyse finale de l’étude PEARL ciblée sur la prévention de la migraine en conditions réelles a été présentée au 11ᵉ congrès de l’Académie européenne de neurologie (le congrès EAN 2025) qui s’est tenu à Helsinki 1,2 [...]
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
24/06/2025
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, [...]
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
24/06/2025
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) [...]

Pages